ModernaTX, Inc. clinical trials

A subsidiary of Moderna, Inc.

The registry lists 117 studies whose lead sponsor is ModernaTX, Inc.. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 117. List all 117 → · All Moderna, Inc. studies →

• A Study of Updated mRNA Seasonal Influenza VaccinesNot yet recruitingNCT07884175Phase 4

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsRecruitingNCT06880549Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenNot yet recruitingNCT07870330Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNot yet recruitingNCT07863635Phase 4

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07116616Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsRecruitingNCT06655870Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNot yet recruitingNCT07808697Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy AdultsRecruitingNCT07764237Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsRecruitingNCT05533697Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsRecruitingNCT06735248Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsRecruitingNCT06585241Phase 4

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeRecruitingNCT07478952Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyRecruitingNCT05130437Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Retrospective Study to Characterize Participants With Propionic AcidemiaRecruitingNCT05769621

  Sponsor listed in the registry: ModernaTX, Inc.

• Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaRecruitingNCT04159103Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705RecruitingNCT05295433Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeCompletedNCT05992935Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)CompletedNCT06508320Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeCompletedNCT05127434Phase 2/3

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingNCT07266558Phase 4

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult ParticipantsActive, not recruitingNCT07737717Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeCompletedNCT06602024Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)Active, not recruitingNCT03897881Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsActive, not recruitingNCT03313778Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsCompletedNCT06067230Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusCompletedNCT06097299Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsActive, not recruitingNCT05831111Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsActive, not recruitingNCT07496450Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Active, not recruitingNCT05683457Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeTerminatedNCT05701800Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)Active, not recruitingNCT07561294Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of AgeCompletedNCT05975099Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsCompletedNCT07089706Phase 4

  Sponsor listed in the registry: ModernaTX, Inc.

• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsActive, not recruitingNCT05743881Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersCompletedNCT06143046Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeCompletedNCT05575492Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisActive, not recruitingNCT06592794Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesCompletedNCT06033261Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsActive, not recruitingNCT05164094Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaTerminatedNCT04899310Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsCompletedNCT04232280Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeCompletedNCT07117487Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19CompletedNCT05815498Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGEActive, not recruitingNCT06333704

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of AgeCompletedNCT06634797Phase 4

  Sponsor listed in the registry: ModernaTX, Inc.

• A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineCompletedNCT04975893Phase 2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of AgeCompletedNCT05330975Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsCompletedNCT05827926Phase 1/2

  Sponsor listed in the registry: ModernaTX, Inc.

• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeTerminatedNCT05085366Phase 3

  Sponsor listed in the registry: ModernaTX, Inc.